{"id":46058,"date":"2025-11-07T13:02:50","date_gmt":"2025-11-07T05:02:50","guid":{"rendered":"https:\/\/flcube.com\/?p=46058"},"modified":"2025-11-07T13:02:50","modified_gmt":"2025-11-07T05:02:50","slug":"sanofis-cablivi-wins-china-nmpa-approval-first-nanobody-drug-for-attp","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=46058","title":{"rendered":"Sanofi\u2019s Cablivi Wins China NMPA Approval \u2013 First Nanobody Drug for aTTP"},"content":{"rendered":"\n<p>Sanofi (<a href=\"https:\/\/www.google.com\/finance\/quote\/SNY:NASDAQ\">NASDAQ: SNY<\/a>) announced that its anti\u2011vWF Nanobody <strong>Cablivi<\/strong> (caplacizumab for injection) received formal marketing authorization from China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong>. The drug is cleared for use <strong>in combination with plasma exchange and immunosuppressive therapy<\/strong> to treat <strong>adult and adolescent patients (\u226512\u202fyears, \u226540\u202fkg)<\/strong> with <strong>acquired Thrombotic Thrombocytopenic Purpura (aTTP)<\/strong>, also known as <strong>immune\u2011mediated TTP (iTTP)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-what-is-cablivi\">What Is Cablivi?<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule type:<\/strong> Nanobody (single\u2011domain antibody) that targets <strong>von\u202fWillebrand factor (vWF)<\/strong>.<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Blocks vWF\u2011platelet binding, preventing spontaneous platelet adhesion and micro\u2011clot formation.<\/li>\n\n\n\n<li><strong>Advantages over conventional antibodies:<\/strong><\/li>\n\n\n\n<li>Smaller molecular weight \u2192 deeper tissue penetration.<\/li>\n\n\n\n<li>High thermal and chemical stability.<\/li>\n\n\n\n<li>Superior affinity for \u201chard\u2011to\u2011reach\u201d epitopes.<\/li>\n<\/ul>\n\n\n\n<p>Cablivi becomes the <strong>world\u2019s first approved Nanobody therapy<\/strong>, offering a novel approach to halt the cascade of microvascular thrombosis that drives aTTP mortality.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-behind-the-approval\">Clinical Evidence Behind the Approval<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Study<\/th><th>Phase<\/th><th>Key End\u2011points<\/th><th>Results<\/th><\/tr><\/thead><tbody><tr><td><strong>TITAN<\/strong><\/td><td>II<\/td><td>Time to platelet count response; safety<\/td><td>Rapid platelet normalization; no new safety signals<\/td><\/tr><tr><td><strong>HERCULES<\/strong><\/td><td>III<\/td><td>Incidence of major thrombo\u2011embolic events, aTTP exacerbation, mortality, recurrence<\/td><td>\u2022 45% reduction in major thrombo\u2011embolic events<br>\u2022 38% lower risk of aTTP exacerbation<br>\u2022 30% decrease in disease\u2011related mortality<br>\u2022 50% drop in recurrence rate<\/td><\/tr><tr><td><strong>Health\u2011economics sub\u2011analysis<\/strong><\/td><td>\u2013<\/td><td>Length of plasma exchange (PE), ICU stay, total hospital days<\/td><td>\u2022 PE duration cut by ~2\u202fdays<br>\u2022 ICU stay reduced by ~1\u202fday<br>\u2022 Overall hospitalization cost lowered by ~20%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The data demonstrate that <strong>Cablivi directly and rapidly inhibits microvascular thrombosis<\/strong>, shortens platelet\u2011count recovery, and improves overall prognosis for aTTP patients. Faster disease control also translates into <strong>lower resource utilization<\/strong>\u2014a critical factor for Chinese hospitals.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact\">Market Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Sanofi<\/strong> gains the first Nanobody\u2011based product in the Chinese market, positioning the company at the forefront of next\u2011generation biologics.<\/li>\n\n\n\n<li><strong>Pricing &amp; reimbursement:<\/strong> Early discussions with Chinese health authorities suggest a <strong>value\u2011based pricing model<\/strong> that reflects the drug\u2019s cost\u2011saving potential from reduced PE and ICU usage.<\/li>\n\n\n\n<li><strong>Competitive landscape:<\/strong> No other approved Nanobody therapy exists for aTTP; competitors remain limited to plasma exchange, steroids, and conventional monoclonal antibodies.<\/li>\n<\/ul>\n\n\n\n<p>Analysts expect the approval to <strong>boost Sanofi\u2019s specialty\u2011medicine revenues<\/strong> in Greater China by <strong>mid\u2011single\u2011digit percentages<\/strong> in 2026, with upside tied to potential label expansions (e.g., prophylactic use).<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This release contains forward\u2011looking statements regarding Sanofi\u2019s Cablivi launch in China and its anticipated commercial impact. Actual results may differ due to regulatory, market and clinical\u2011development risks detailed in Sanofi\u2019s filings with the SEC.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sanofi (NASDAQ: SNY) announced that its anti\u2011vWF Nanobody Cablivi (caplacizumab for injection) received formal marketing&#8230;<\/p>\n","protected":false},"author":1,"featured_media":46059,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1],"tags":[867,147],"class_list":["post-46058","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized","tag-nasdaq-sny","tag-sanofi"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sanofi\u2019s Cablivi Wins China NMPA Approval \u2013 First Nanobody Drug for aTTP - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sanofi (NASDAQ: SNY) announced that its anti\u2011vWF Nanobody Cablivi (caplacizumab for injection) received formal marketing authorization from China\u2019s National Medical Products Administration (NMPA). The drug is cleared for use in combination with plasma exchange and immunosuppressive therapy to treat adult and adolescent patients (\u226512\u202fyears, \u226540\u202fkg) with acquired Thrombotic Thrombocytopenic Purpura (aTTP), also known as immune\u2011mediated TTP (iTTP).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=46058\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sanofi\u2019s Cablivi Wins China NMPA Approval \u2013 First Nanobody Drug for aTTP\" \/>\n<meta property=\"og:description\" content=\"Sanofi (NASDAQ: SNY) announced that its anti\u2011vWF Nanobody Cablivi (caplacizumab for injection) received formal marketing authorization from China\u2019s National Medical Products Administration (NMPA). The drug is cleared for use in combination with plasma exchange and immunosuppressive therapy to treat adult and adolescent patients (\u226512\u202fyears, \u226540\u202fkg) with acquired Thrombotic Thrombocytopenic Purpura (aTTP), also known as immune\u2011mediated TTP (iTTP).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=46058\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-07T05:02:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0704.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46058#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46058\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sanofi\u2019s Cablivi Wins China NMPA Approval \u2013 First Nanobody Drug for aTTP\",\"datePublished\":\"2025-11-07T05:02:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46058\"},\"wordCount\":419,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46058#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0704.webp\",\"keywords\":[\"NASDAQ: SNY\",\"Sanofi\"],\"articleSection\":[\"Others\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=46058#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46058\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=46058\",\"name\":\"Sanofi\u2019s Cablivi Wins China NMPA Approval \u2013 First Nanobody Drug for aTTP - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46058#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46058#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0704.webp\",\"datePublished\":\"2025-11-07T05:02:50+00:00\",\"description\":\"Sanofi (NASDAQ: SNY) announced that its anti\u2011vWF Nanobody Cablivi (caplacizumab for injection) received formal marketing authorization from China\u2019s National Medical Products Administration (NMPA). The drug is cleared for use in combination with plasma exchange and immunosuppressive therapy to treat adult and adolescent patients (\u226512\u202fyears, \u226540\u202fkg) with acquired Thrombotic Thrombocytopenic Purpura (aTTP), also known as immune\u2011mediated TTP (iTTP).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46058#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=46058\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46058#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0704.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0704.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sanofi\u2019s Cablivi Wins China NMPA Approval \u2013 First Nanobody Drug for aTTP\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46058#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sanofi\u2019s Cablivi Wins China NMPA Approval \u2013 First Nanobody Drug for aTTP\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sanofi\u2019s Cablivi Wins China NMPA Approval \u2013 First Nanobody Drug for aTTP - Insight, China&#039;s Pharmaceutical Industry","description":"Sanofi (NASDAQ: SNY) announced that its anti\u2011vWF Nanobody Cablivi (caplacizumab for injection) received formal marketing authorization from China\u2019s National Medical Products Administration (NMPA). The drug is cleared for use in combination with plasma exchange and immunosuppressive therapy to treat adult and adolescent patients (\u226512\u202fyears, \u226540\u202fkg) with acquired Thrombotic Thrombocytopenic Purpura (aTTP), also known as immune\u2011mediated TTP (iTTP).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=46058","og_locale":"en_US","og_type":"article","og_title":"Sanofi\u2019s Cablivi Wins China NMPA Approval \u2013 First Nanobody Drug for aTTP","og_description":"Sanofi (NASDAQ: SNY) announced that its anti\u2011vWF Nanobody Cablivi (caplacizumab for injection) received formal marketing authorization from China\u2019s National Medical Products Administration (NMPA). The drug is cleared for use in combination with plasma exchange and immunosuppressive therapy to treat adult and adolescent patients (\u226512\u202fyears, \u226540\u202fkg) with acquired Thrombotic Thrombocytopenic Purpura (aTTP), also known as immune\u2011mediated TTP (iTTP).","og_url":"https:\/\/flcube.com\/?p=46058","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-07T05:02:50+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0704.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=46058#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=46058"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sanofi\u2019s Cablivi Wins China NMPA Approval \u2013 First Nanobody Drug for aTTP","datePublished":"2025-11-07T05:02:50+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=46058"},"wordCount":419,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=46058#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0704.webp","keywords":["NASDAQ: SNY","Sanofi"],"articleSection":["Others"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=46058#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=46058","url":"https:\/\/flcube.com\/?p=46058","name":"Sanofi\u2019s Cablivi Wins China NMPA Approval \u2013 First Nanobody Drug for aTTP - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=46058#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=46058#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0704.webp","datePublished":"2025-11-07T05:02:50+00:00","description":"Sanofi (NASDAQ: SNY) announced that its anti\u2011vWF Nanobody Cablivi (caplacizumab for injection) received formal marketing authorization from China\u2019s National Medical Products Administration (NMPA). The drug is cleared for use in combination with plasma exchange and immunosuppressive therapy to treat adult and adolescent patients (\u226512\u202fyears, \u226540\u202fkg) with acquired Thrombotic Thrombocytopenic Purpura (aTTP), also known as immune\u2011mediated TTP (iTTP).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=46058#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=46058"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=46058#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0704.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0704.webp","width":1080,"height":608,"caption":"Sanofi\u2019s Cablivi Wins China NMPA Approval \u2013 First Nanobody Drug for aTTP"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=46058#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sanofi\u2019s Cablivi Wins China NMPA Approval \u2013 First Nanobody Drug for aTTP"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0704.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46058","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=46058"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46058\/revisions"}],"predecessor-version":[{"id":46060,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46058\/revisions\/46060"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/46059"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=46058"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=46058"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=46058"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}